Showing 13–24 of 46 results

  • Placeholder

    Crizalk (Crizotinib) – 250 Mg

    0 out of 5
    Price range: $868 through $1,727

    Crizalk 250 mg is an oral capsule formulation of crizotinib, a precision tyrosine kinase inhibitor developed for treatment of advanced or metastatic non‑small cell lung cancer (NSCLC) with specific genetic alterations. It inhibits ALK, ROS1, and MET‑exon 14 skipping mutations to halt cancer cell proliferation and improve survival outcomes in responsive patients.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Cycloxan 50 Mg (Cyclophosphamide)

    0 out of 5
    Price range: $58 through $165

    Cycloxan 50 mg is a chemotherapy tablet containing Cyclophosphamide, widely used in the treatment of various cancers, including leukemia, lymphoma, breast cancer, and ovarian cancer. It works by interfering with the growth of cancer cells, stopping them from multiplying. Cycloxan is taken orally and may be used as part of combination chemotherapy depending on the condition.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Cytomid (Flutamide) – 250 Mg

    0 out of 5
    Price range: $13 through $37

    Cytomid 250 mg contains flutamide, a non‑steroidal antiandrogen medication used in the treatment of prostate cancer. It works by blocking androgen receptors, thereby reducing the effect of testosterone on prostate tumor cells. Typically prescribed alongside surgical or medical castration methods, Cytomid helps to enhance cancer control in androgen-sensitive disease

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Cytotam Tamoxifen 20 Mg

    0 out of 5
    Price range: $27 through $90

    Cytotam 20 mg is an oral tablet containing tamoxifen, a widely used selective estrogen receptor modulator. It binds to estrogen receptors in breast tissue, preventing estrogen from stimulating the growth of hormone‑receptor positive tumors. Indications include adjuvant therapy for early breast cancer, treatment of metastatic disease, and risk reduction in high-risk women.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Dexona (Dexamethasone) – 0.5 Mg

    0 out of 5
    Price range: $9 through $29

    Dexona 0.5 mg is a low‑dose oral tablet formulation containing dexamethasone, a potent systemic corticosteroid. It suppresses inflammation and modulates the immune response. Used in managing conditions such as asthma, arthritis, allergic reactions, dermatological disorders, and as adjunctive therapy in infections or cancer care—all under close physician guidance.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Flonida Cream 5% (Fluorouracil)

    0 out of 5
    Price range: $8 through $44

    Flonida Cream is a topical formulation containing 5% fluorouracil, a potent antimetabolite used in treating precancerous and superficial cancerous skin lesions. It works by inhibiting abnormal cell growth in damaged skin, making it ideal for treating actinic keratosis and superficial basal cell carcinoma. The cream offers localized, non-invasive therapy with minimal systemic absorption.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Geftinat (Gefitinib) – 250 Mg

    0 out of 5
    Price range: $309 through $999

    Geftinat 250 mg is an oral tablet containing gefitinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‑TKI). It is indicated for treating adult patients with advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have specific EGFR gene mutations. By inhibiting EGFR signaling, Geftinat helps block cancer cell proliferation and progression.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Hydrea (Hydroxyurea) – 500 Mg

    0 out of 5
    Price range: $20 through $56

    Hydrea 500 mg is a prescription cytotoxic antimetabolite containing hydroxyurea. It is used in:

    • Chronic myeloid leukemia (CML) to reduce leukocyte counts and control disease

    • Head and neck cancers and other solid tumors as part of chemotherapy regimens

    • Sickle cell disease to reduce vaso-occlusive crises and red cell sickling

    Hydroxyurea works by inhibiting ribonucleotide reductase, suppressing DNA synthesis in rapidly dividing cells. It may also promote fetal hemoglobin production, reducing sickling in sickle cell patients.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Imat (Imatinib) – 100 Mg

    0 out of 5
    Price range: $57 through $165

    IMAT 100 mg is an oral tablet formulation of imatinib, a selective tyrosine kinase inhibitor (TKI). It is indicated for adult patients with chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), and c-KIT+ gastrointestinal stromal tumors (GIST). Imatinib targets BCR-ABL, c-KIT, and PDGFR tyrosine kinases, effectively blocking malignant cell growth and disease progression.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Imat 400 Mg (Imatinib)

    0 out of 5
    Price range: $130 through $375

    IMAT 400 mg is a higher-strength oral tablet formulation of imatinib, a selective tyrosine kinase inhibitor (TKI). It’s indicated for patients with advanced or resistant chronic myeloid leukemia (CML), Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), and c-KIT+ gastrointestinal stromal tumors (GIST). By inhibiting BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases, imatinib halts cancer cell growth and improves disease outcomes.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Imatib 100 Mg

    0 out of 5
    Price range: $123 through $399

    Imatib 100 mg is a tablet containing imatinib mesylate, a selective tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. It’s approved for treating chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and c-KIT-positive gastrointestinal stromal tumors (GIST). By blocking key cancer-driving enzymes, Imatib helps to suppress disease progression and induce remission.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page
  • Placeholder

    Imatib 100 Mg

    0 out of 5
    Price range: $123 through $399

    Imatib 100 mg is a targeted therapy medicine containing Imatinib, used to treat certain types of blood and stomach cancers including Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GIST). It works by blocking abnormal protein signals that cause cancer cells to grow. Imatib is often prescribed as a long-term treatment, helping improve survival and reduce recurrence in patients with cancer-related gene mutations.

    Select optionsDone This product has multiple variants. The options may be chosen on the product page

End of content

End of content